Agios Pharmaceuticals, Inc. (AGIO) Earnings Call Transcript & Summary
February 13, 2025
Earnings Call Speaker Segments
Marc Frahm
analystThanks, operator. Morning, everyone, and I appreciate you being here on the Agios call and webcast. Today we're covering our Q4 and full-year 2024 financial results, along with what's new in the business. You can find the slides for this call on our website, agios.com, under the Investors section. With me are Brian Goff, our CEO; Dr. Sarah Gheuens, who serves as Chief Medical Officer and Head of Research and Development; Tsveta Milanova, our Chief Commercial Officer; and Cecilia Jones, our Chief Financial Officer. Before we get started, I want to point out that some of what we say today will include forward-looking statements. Because of various risks, uncertainties and other factors — including those described in our most recent SEC filings and any future filings we make with the SEC — actual events and results may differ materially from what those forward-looking statements express or imply. With that, I'm happy to hand the call to Brian.
Brian Goff
executiveThank you, Chris. Good morning, all, and thanks for being with us. Agios exists to develop and deliver transformative medicines that lift up and lengthen the lives of people suffering from rare diseases; our particular focus is on rare diseases causing dysfunction and disruption of red blood cells, among them pyruvate kinase deficiency, thalassemia, sickle cell disease, and lower-risk myelodydylastic syndromes, or MDS. PYRUKYND is our primary offering — a pyruvate kinase activator with a mechanism unlike any other. What it does is boost the way red blood cells handle metabolism, increasing the amount of energy, known as ATP, that's on hand to keep those cells healthy. We're happy today to walk you through how we did in the fourth quarter, to revisit our achievements over the course of 2024, and to outline our expectations for what should be an exciting year ahead. Our uncommon roadmap to success places us in a unique spot to drive meaningful near-term and long-term gains in shareholder value. To start with, there's the thrilling possibility of 2 more commercial launches, which we believe underpin a multibillion-dollar growth opportunity tied to PYRUKYND, our lead product. First, regarding thalassemia, we're getting ready for a potential approval and launch this September, and sickle cell disease should come after that in 2026. Next, we have a robust early and mid-stage pipeline that's prepared to move into clinical development, which gives us a dependable foundation for both innovation and expansion. Last, supporting all of this is our highly seasoned team — one that has proven it can execute at a high level — plus a healthy balance sheet. That combination puts us in the fortunate spot of being able to expand this company on our own and pursue these promising opportunities. For Agios, 2024 was a remarkable year on both the scientific and operational fronts. As this slide shows, each significant milestone we had projected a year ago now has a checkmark next to it. We achieved considerable progress across all of our lead programs — including filing for regulatory approval in thalassemia in 4 markets and completing patient enrollment for our Phase III RISE up trial in sickle cell disease. Meanwhile, our early-stage pipeline continues to advance, creating a foundation for sustained growth over the long term. With such a transformative 2024 behind us, we view 2025 as a breakout year for Agios. Across the coming 12 months, 3 key priorities will guide us: first, realizing the fullest potential of the PYRUKYND franchise; second, pushing forward and diversifying our main pipeline programs and third, directing our capital deployment strategically so we can sustain and propel our growth. And building on everything achieved in 2024, another year lies ahead filled with compelling commercial, regulatory and clinical milestones. Today, we reported top line results from the ACTIVATE KIDS Phase III trial evaluating mitapivat in pediatric patients with PK deficiency who are not regularly transfused. For Agios, this represents the company's initial pediatric trial of mitapivat targeting a rare hemolytic anemia, and we're eager for Sarah to walk you through the encouraging top line results from that study in the near future. Beyond that, we're anticipating several noteworthy milestones across our mid- and early-stage pipeline efforts. Turning to TevaPIVac, the novel PK activator formerly known as AG-946: we expect to wrap up enrollment in the current Phase IIb trial in lower-risk MDS before the year is out, and to kick off a Phase II study in sickle cell disease by the middle of 2025. Beyond that, we intend to file an investigational new drug application around the middle of 2025 for AG-236 — that's the siRNA aimed at 106 inhibition — which we're developing to treat polycythemia vera. Looking ahead to 2025, the biggest events we anticipate are the September 7 PDUFA goal date tied to our sNDA submission for PYRUKYND in thalassemia, along with the Phase III data readout from the RISE trial of mitapivat in sickle cell disease, expected before the year ends. So as you can tell, there's a lot to look forward to this year, with numerous catalysts throughout our pipeline that carry substantial value for shareholders and could be truly transformative for patients. Having covered those opening remarks, I'll now pass things over to Sarah, who will walk us through our exciting R&D progress.
Sarah Gheuens
executiveThank you, Brian. In our pipeline, you'll find a balanced combination of late-stage assets that are close to reaching the market alongside encouraging programs in the mid- and early stages, all of which demonstrate the depth and breadth of our therapeutic work. We focus on those opportunities where our know-how and capabilities can deliver a measurable difference and generate substantial value. You may have seen that we released top-line results earlier today from Activate-Kids, the second of our Phase III pediatric studies, evaluating mitapivat in children with PK deficiency who aren't on regular transfusions. That goes alongside the Phase III activated T trial of mitapivat in pediatric PK deficiency patients receiving routine transfusions, whose top-line data came out in August of last year. Turning to what Activate-Kids showed: a total of 30 patients, ages 1 to under 18, took part, with 19 randomized to mitapivat given twice daily and 11 randomized to matching placebo. All patients in both groups completed the 20-week double-blind phase. The main goal of the trial was hemoglobin response, which we defined as a rise in hemoglobin concentration of at least 1.5 grams per deciliter from baseline that was maintained across two or more of the scheduled assessments at weeks 12, 16 and 20 in the double-blind period. That primary endpoint was met. In the mitapivat group, a hemoglobin response occurred in 31.6%, or 6 of 19 patients, compared with 0%, or 0 of 11 patients, in the placebo group; on top of that, the mitapivat arm showed improvements in changes from baseline for hemolysis markers relative to the placebo arm. Across the 20-week double-blind phase, the share of patients experiencing adverse events was similar between those receiving mitapivat and those on placebo, and no one stopped study treatment because of adverse events for any reason. The safety results were consistent with what has previously been observed for mitapivat in adult PK deficiency patients who do not receive regular transfusions; now that we have data from the randomized, placebo-controlled, double-blind portion of both Phase III pediatric PK deficiency trials, we are eager to share fuller details with the community and to engage with regulators. Agios ran its first pediatric trial for a rare hemolytic anemia through the Phase III ACTIVATE-KIDS and ACTIVATE-KIDS studies, and what we learned there will be valuable as we design upcoming clinical programs that test mitapivat in pediatric thalassemia and sickle cell disease patients. Let's shift to thalassemia. It's an inherited blood disorder that patients live with for their entire lives, causing chronic anemia, and those affected frequently deal with a variety of debilitating complications, including organ damage, stroke, and other serious health problems. The standard approaches to managing thalassemia, for example blood transfusions along with iron collation therapy, may themselves produce considerable secondary effects, which adds further to the health difficulties these patients already endure. Right now, those with this diagnosis have few, if any, good ways to get treated — in America, 67% of people who receive this diagnosis lack any sanctioned therapeutic choices. In 2024, we shared positive results from the energized and energized Phase III trial, which evaluated mitapivat versus placebo in grown-ups suffering from non-transfusion-dependent and transfusion attendant alpha or beta thalassemia, correspondingly. Over on the left side of this slide, a top line summary of what these 2 studies found is displayed. Because of the positive benefit/risk profile observed throughout both the energized and enterprise Phase III studies, we think mitapivat may turn into a basic and handy oral drug for thalassemia patients no matter their genotype or transfusion needs. Back in December, we shared news that we had submitted regulatory filings all at once for PYRUKYND in this indication across four territories: the U.S., the European Union, the Kingdom of Saudi Arabia and the United Arab Emirates. Then last month, we let everyone know the FDA had accepted our supplemental new drug application, setting a PDUFA goal date of September 7, 2025. Moving on now to sickle cell disease. Roughly 120,000 to 135,000 people in the U.S. and EU5 are thought to live with this inherited, lifelong blood disorder, and worldwide prevalence tops 3 million. Chronic hemolytic anemia and vaso-occlusion are the clinical hallmarks of sickle cell disease, and these can bring about pain that harms quality of life, organ damage and death at an early age. Patients dealing with this devastating and potentially fatal condition desperately need innovative treatment approaches that can raise the bar for care. Given what we observed in our Phase II RISE Up trial — favorable outcomes — plus promising findings from other hemolytic anemias sharing the same underlying pathophysiology, we believe mitapivat holds considerable promise for sickle cell disease too. Enrollment for the Phase III RISE Up study wrapped up in October 2024, with more than 200 participants signed up across the globe, a milestone reached only slightly more than twelve months after the improvement launched. This trial features two separate primary endpoints: hemoglobin response and the annualized rate of sickle cell pain crises. Having dual primary endpoints enables us to direct alpha toward the trial's secondary end points. When it comes to the secondary endpoints, we're evaluating mitapivat's promise for helping patients feel and function better through a range of different measures. Top line results from the Phase III study should be available to us in late 2025, and that would be followed by a regulatory filing, with possible U.S. approval in 2026; in our view, mitapivat could become a best-in-class therapy that tackles the significant unmet need in this disease by improving anemia, cutting down on sickle cell pain crises, and helping patients feel better overall. Now I'd like to briefly update everyone on DevatIVA, which right now is being studied as a possible treatment for low-risk MDS in sickle cell disease. In the case of lower-risk MDS, our goal is to provide the first pill-based treatment targeting anemia caused by ineffective erythropoiesis in this condition. Roughly 75,000 to 80,000 people across the U.S. and EU5 have this disease, and lower-risk MDS makes up about 70% of all MDS cases. Last year, we launched a Phase IIb study of tevapipat Viva in MDS, which has 3 arms dosed at 10, 15, and 20 milligrams — all of them higher than the 5-milligram level given in the Phase IIa study. Enrollment is progressing well, and we're still on track to complete patient accrual by the close of this year. Additionally, back in September of last year, the FDA granted orphan drug designation to tevapipat for this indication, underscoring the importance of offering an oral treatment option to patients dealing with this rare disease. Regarding sickle cell disease, given the substantial unmet need along with how varied the condition can be, physicians treating it emphasize the value of having multiple therapeutic options available. In 2024, we presented Phase I data on tevapipat for sickle cell disease at the ASH annual meeting. Building on those results, we will move this clinical program forward into Phase II development, with patient enrollment anticipated to start in mid-2025; having said that, I will now hand the call over to Sarah.
Tsveta Milanova
executiveAppreciate that, Sarah. Looking ahead to 2026, there's a real opportunity to broaden Biocon's indications so they cover thalassemia and sickle cell disease, which would serve these 2 patient groups that remain highly underserved. We expect to launch in thalassemia later this year, and our goal is to bring forward the first therapy approved to address every subtype of that disease. When it comes to sickle cell, we intend to offer a novel oral treatment that tackles anemia, cuts down vaso-occlusive crises — VOCs — and lessens fatigue. By taking biokine into these 2 bigger patient populations, our objective is to reshape how these diseases are treated, which in turn opens up a multibillion-dollar opportunity for the company and for our shareholders. Our team is working hard to get ready for a possible near-term thalassemia launch, with 3 main priorities. First, we're running a strong disease state education effort covering the pathology, the long-term complications, existing standards of care, and why regular monitoring and management matter. Second, we're right-sizing our cross-functional field team so this launch succeeds in a larger yet < > market. As an example, for PK deficiency our sales force was set at 18 to 20 professionals. For thalassemia, we've deliberately expanded the sales organization to roughly double that figure; and third, we're actively reaching out to and informing payers about thalassemia to build disease understanding and help patients get access. Roughly 6,000 adults have a leukemia diagnosis in the U.S., and most of them are diagnosed before paddled food. Thanks to claims data being available, we can pinpoint where these patients receive care across the health care system, which gives us useful clarity as we prepare for launch. Among that group, we estimate that < > initial launch problems, we reach about 65% of the adult leukemia patient population. We anticipate that patients who have more frequent contact with the health care system because of their symptoms will be evaluated for therapy first; that includes those who are transfuse dependent along with those who are nontransfusion dependent and already dealing with complications or debilitating fatigue. Our team stays active in the field, continually building our knowledge of these varied patient segments and the multi-cultural aspects of the disease. As the launch opportunities we pursue keep getting bigger, we're grounding ourselves in the transformative profile of biotin in thalassemia, defined by a number of < > . This could be the first therapy for both alpha and state thalassemia patients, the first oral option for the disease, the first treatment showing quality of life gains for non-transfusion dependent patients, and the first to demonstrate 36 with durability of effect in lowering transfusion burden. That's what drives us to the lower < > to people suffering from thalassemia as quickly as possible. Lastly, let me give a quick update on the ongoing PYRUKYND launch in PK deficiency. During 2024's fourth quarter, net PYRUKYND revenue reached $10.7 million, up from $9 million in 2024's third quarter. Across the U.S., 223 patients altogether have finished a prescription enrollment form, among them 12 during 2024's fourth quarter, which marks a 6% rise over the preceding quarter; that has converted into 113 net patients receiving therapy for this ultra-rare disease. The capabilities we keep reinforcing amid the present launch, we believe, will supply a solid base for maximizing potential upcoming U.S. launches of PYRUKYND in thalassemia during 2025 and in sickle cell disease during 2026. As we look toward the coming month, our team will keep honing its attention on getting ready for launch, with thalassemia as our top priority; the commercial potential of thalassemia excites us. Three factors drive this: patients receive diagnoses and are recognized by the health care system. Disease burden is thoroughly characterized, and care and patient advocacy groups are well established; we trust that these elements, alongside our strong preparation, will clear the path toward a successful launch; to wrap up, the prospect of delivering a new therapy to the underrate population globally inspires and energizes us. With that, I'll hand the call to Cecilia.
Cecilia Jones
executiveAppreciate that, Tsveta. You can find our financial results for the fourth quarter of 2024 in the press release that went out this morning, and additional detail is going to be in our 10-K, which gets filed later on today. So let me take a moment here to give some context and walk through a handful of key points. Net < > revenue for the fourth quarter of 2024 came in at $10.7 million, which is a 51% increase over the $7.1 million we recorded in the fourth quarter of 2023. We'd note that Q4 2024 revenue was higher mainly because of year-end stocking along with adjustments to certain revenue reserves. Those items account for roughly $1.6 million in Q4, and we don't anticipate them recurring in the first quarter of 2025. Although it was lower in the fourth quarter of 2024, gross to net has typically been, and is expected to remain, within the 10% to 20% range on an annual basis, in line with other rare disease launches, and it will see variability from quarter to quarter. Cost of sales for the quarter came to $1.3 million. R&D expenses totaled $82.8 million for the fourth quarter, up $5.3 million versus the fourth quarter of 2023; that was mainly the result of workforce related expenses. G&A expenses came in at $51.7 million for the fourth quarter, an increase of $16.4 million versus the prior year quarter. That was mainly the result of a rise in commercial-related activities as we get ready for the possible approval of PYRUKYND in thalassemia in 2025; worth noting, we received a total of $1.1 billion in milestone payments after the FDA approval of vorasidenib, and those were recorded in the third quarter. Those payments consisted of a $905 million payment from Royalty Pharma tied to the vorasidenib royalty purchase agreement we announced in May 2024, plus a $200 million payment from Servier tied to the divestiture of its oncology business in 2021. As a reminder, Agios will keep a 3% royalty on annual U.S. net sales of vorasidenib above $1 billion. With all of that factored in, we closed the fourth quarter with cash, cash equivalents and marketable securities of roughly $1.5 billion. We expect this balance, along with anticipated product revenue and interest income, to give us the financial independence to prepare for possible biogene launches in thalassemia and sickle cell disease, advance existing programs and opportunistically expand our pipeline through assets discovered both internally and externally. Looking ahead, and with our PDUFA date in sight, we are shifting our focus toward preparing for the possible launch in thalassemia, and we expect 2025 revenues for PK deficiency to be relatively flat versus 2024. On thalassemia, it's worth reminding everyone that it can take several weeks, particularly at launch, between the prescription enrollment form and a patient starting therapy. Combined with the expected time needed to set up payer access, we're looking at more of a partial quarter in Q4, which should be factored into modeling revenue expectations for 2025. Clearly, we can't wait for the PDUFA date on September 7 to get here, and the team has prepared thoroughly for it. As we look at 2026 and the years after, we have confidence in the team's capacity to turn the favorable market dynamics I mentioned earlier into a substantial revenue trajectory for thalassemia; to wrap up, we stay committed to building shareholder value, which includes actively managing our cost base and taking a disciplined approach to cash allocation as we get ready to back possible future launches of < >. With additional potential value-creating milestones on the near-term horizon, I have no doubt that our balance sheet will keep allowing us to operate from a position of strength. At this point, I'll hand the call back to Brian.
Brian Goff
executiveThank you, Cecelia. Ahead of wrapping up, there's another item from this morning's press release I want to call attention to. Dr. David Schenkein has let us know that as of February 28, 2025, he will be leaving our Board of Directors so he can give more of his time to other commitments. He'll stay on in the capacity of strategic adviser to Agios' leadership team, with his focus on moving the company's clinical development programs forward. David's tenure at Agios spans 15 years, 10 of them as the company's CEO, and he was a Board of Directors member the whole time. . For my part, I'd like to express my gratitude to David for the friendship, mentorship, and guidance he has offered throughout my entire tenure leading Agios. He played an essential part in shaping the company into what it has become. I also want to express, on behalf of everyone at the organization, just how much we value the tremendous contributions he has made—our gratitude is genuine, and we're eager to keep working alongside him as he takes on his new advisory position. At Agios, 2024 was a standout year thanks to remarkable progress; and, as you've already been told, 2025 will bring important regulatory and clinical milestones. We think 2025 is going to be a breakthrough year for this organization, powered by the expected green light and market introduction for PYRUJYND in thalassemia, a key Phase III data disclosure in sickle cell disease, plus significant expected headway throughout our mid- and early-stage programs. Before I finish, I want to quickly echo what Cecilia mentioned. Thanks to our solid financial position, we can move forward on our own with the most important goals: getting the most out of PYRUKYND's launches for thalassemia and sickle cell disease, pushing ahead the clinical programs we already have in early and mid-stage development, and growing our pipeline through internal and external possibilities. We stay dedicated to careful cash management, making sure our healthy balance sheet helps us reach critical milestones and sets us up to keep creating value. We're excited about what's ahead as we work to alter the course of these rare diseases. With that said, I'd like to turn the call over to questions. Operator, please open the line.
Eric Schmidt
analystCongratulations on everything you've achieved so far. I'm excited to see what 2025 brings. Sarah, perhaps we can begin with you: how does the company intend to keep the investment community informed regarding the safety profile for a few batch of NPA? If additional hepatocellular injury cases arise, or any signals show up, what lever exists there? Then Brian, for roughly the last 12 months, I believe you've discussed mitapivat's multibillion dollar opportunity in these further indications. As you build that multibillion dollar estimate, how are you thinking about peak sales potential in either thalassemia or sickle cell disease?
Brian Goff
executiveSure. Thanks, Eric. Sarah, would you like to take the first question?
Sarah Gheuens
executiveAbsolutely, Eric — thanks for asking. Just like we did when we first learned about this new safety information regarding thalassemia, we went ahead and informed the investor community once we reached the point where we could determine that the drug's safety profile had changed. So should anything shift when it comes to the safety profile of the drug as we understand it right now, and once we're able to reach that determination, we would let all of you know as well.
Brian Goff
executiveNow, regarding your second question, Eric, about the multibillion-dollar opportunity we foresee for Parkin — I'd like to say we're quite thrilled about where we stand at this moment, given all the momentum, the clinical data backdrop, and now the PDUFA date for thalassemia that we mentioned. To explain why we hold such strong belief in the long-term potential for thalassemia, as we've stated on several calls, two-thirds of patients in the U.S. lack any approved treatment option, which creates a tremendous opportunity in terms of unmet need for those individuals. When we consider the combined opportunity from both the energize and energized T data, it's a truly compelling profile; so that will clearly be the initial step along that multibillion-dollar path. The second area, sickle cell disease — I believe it's been quite clear to the entire community that unmet need in sickle cell disease has consistently been very high, and it has in fact grown over the past few months, given certain challenges and limitations among available therapeutic options. So that represents a significant step for us as well; and naturally, we'll be in a position to provide further guidance as we progress through these approval pathways, the launch phases, and in the case of sickle cell disease, we're approaching the data readout at the end of this year for the RISE up Phase III study. So a great deal of conviction, all of that with PYRUKYND. And naturally, we're expanding a PK activation franchise beyond that with the advantage of Tebapivat — as we've mentioned, we're conducting a Phase II study in sickle cell disease, and we're already enrolling in our Phase IIb for low-risk MDS; so much opportunity lies ahead.
Divya Rao
analystThis is Divya calling in for Mark. Congratulations on everything you've accomplished. I just have one question about sickle cell. Following the liver tox disclosure at Dow last year, could you share any information about adjustments made to the sickle cell trial protocol? Is it mainly within the OLE portion? Or did the core portion of the trial also see any modifications? And I have a follow-up after that.
Sarah Gheuens
executiveThank you, Divya, for asking; so we — during the court period, so once that call had been made, we examined the monitoring being done across every one of the trials. And we had already been monitoring liver test enzymes in our core period throughout each of our trials during the blinded period, which aligns very closely with the way therapies get started in the real world and how drugs get monitored initially when patients begin treatment. In the open label, we needed to adjust the monitoring frequency. So once a month. to match what we had been doing in the core period of the sickle cell disease trial. So at this point everyone across all of our programs is monitored once a month for the first 6 months of exposure.
Divya Rao
analystThat helps. And regarding Teva, has that been looked into for sickle cell, and what's the way we ought to view the development path in that case? Is it more of a proof of concept ahead of going into other diseases, or, should the trial work, do you in fact intend to proceed into pivotal development for sickle cell with this program?
Brian Goff
executiveYes. Thank you, Divya. I believe I'll ask State to address that from a longer-term commercial standpoint, since, once more, having not just one but two opportunities in this highly complex disease with very high unmet need is a genuine benefit.
Cecilia Jones
executiveSure. So on the combined picture, as Bryan said, there's definitely an unmet need in the patient community, and clinicians tell us loudly and clearly that more than a single treatment option is required, along with more than one < > activator. So where we are right now with < >, we're seeking a chance to build a sickle cell disease franchise spanning both PYRUKYND and < >. When it comes to the specific makeup of the 2 products and how we'll develop < >, the data will guide us. As we always do, we'll need to see the right update. We need to see the < > Phase II data, we'll assess the competitive landscape at that moment, and Sarah and I collaborate very closely to put together a clinical development plan that will both satisfy regulators and be commercially viable for us.
Brian Goff
executivePlus, with the midyear launch getting nearer, we will obviously gain a clearer picture regarding the trial design and precisely how it will be structured.
Gregory Renza
analystGreat. Brian and the team, congratulations on the progress made this year. Brian, maybe just diving into the pipeline a bit, and as you get your hands on the PK activation portfolio, I just wanted to ask about your enthusiasm — how you'd characterize your level of excitement regarding AG-1, the PAH stabilizer. Maybe just remind us of that particular mechanism, how it stabilizes PAH, and perhaps why it ought to work well for patients who don't respond to that co-factor treatment?
Brian Goff
executiveSure. The first thing I'll say, Greg, is that I don't — I don't play favorites among the children in our pipeline; we're truly proud of everything across the pipeline, that's my first comment. The second is that we're in a really strong position from a diversification standpoint within the pipeline, in terms of asset type, disease, and stage of development. Regarding AG-181, a phenylalanine hydroxylase stabilizer, in a sense it's comparable to pyruvate kinase activation, in that it stabilizes the enzyme required for converting phenylalanine, and we're in Phase I now. And naturally, we look forward to providing ongoing updates as we make headway on this development opportunity. But this is a population with very high unmet need. We're talking about 35,000 to 40,000 patients, and only a very small subset of them are actually being actively treated, and frankly, they have very limited options for treatment. So it's another market of excellence that emerged from the Agios development, discovery and development. And once again, it's right in the sweet spot of what we do best at Agios, which has addressed high unmet need, rare diseases, and we definitely look forward to giving you further updates.
Gregory Renza
analystThat's useful, and perhaps a wider question, stepping back a bit. When you consider how you might deploy cash internally and, obviously, externally too, what's your read on the market for outside assets, particularly given how active things are right now, both here at home and around the world?
Brian Goff
executiveYeah, good question. To start, and to build on your point, one of our essential elements as an attractive rare disease business with an extremely promising future is exactly that. We're happy about what I'd describe as the admirable strength of our balance sheet, and that lets us, as our top priority, as I mentioned in my remarks, ensure we get the most out of these launch opportunities. We have thalassemia with the PDUFA date this year. We have sickle cell disease possibly next year after the rise up readout. So that's priority one. Priority 2 is, as you just asked, we have additional mid- and early-stage products in our pipeline. We want to ensure we keep hitting those value-creating inflection points. And then, to your question, we've actually expanded our business development capabilities, especially when it comes to search and evaluation. I believe it matters that — as any healthy company would, we must be highly disciplined in that approach. But we're quite clear about what would fit well with the Agios rare disease capabilities, which keep growing, especially on the commercial side; and we look domestically, and we also have global line of sight too; but we'll be very thoughtful and disciplined about where we think we can add significant value creation.
Greg Harrison
analystNice work on the advancement. I'm curious how you believe investors ought to frame the mitapivat launch curve for thalassemia, possibly during 2026 — I recognize that securing access takes some time and there will be a delay before treatment starts in 4Q. Even so, do you anticipate pent-up demand or an early bolus within certain of those patient populations you mentioned as the first launch priority?
Brian Goff
executiveYeah. Appreciate it, Greg. Let me begin by saying I feel a great deal of pride in Tsveta and the whole commercial team she leads, given how committed they've been to disease state education for thalassemia in particular, which this field truly requires. We're in a strong position and ready for the PDUFA date coming in September. And Cecilia, would you like to weigh in on how those dynamics might shape up as the year winds down?
Cecilia Jones
executiveYes, of course. I appreciate you asking that. Everyone on the team is putting in a great deal of effort getting ready for the launch. We're genuinely thrilled about the chance to bring these treatment choices to patients across the U.S. As you pointed out, we've shared guidance regarding where we'll focus initially, and that reaches roughly 65% of the adult thalassemia population in the U.S. — that's 4,000 out of 6,000 total. On the launch side, we're certainly doing education work to build a sense of urgency around acting and monitoring 3 patients. That said, an initial bolus of patients isn't something they anticipate, since people see their doctors on a regular visit schedule that depends on whether they're transfusion-dependent or non-transfusion-dependent, along with complications; so our expectation is that we'll pick up these patients as they arrive. And naturally, we'll keep up the disease education so the right conversations are taking place, allowing them to select the most suitable option for the best possible treatment going forward.
Brian Goff
executiveRight. And honestly, that's just smart triage as well. When we talk about 65% targeting, that obviously doesn't mean the remaining 35% never gets targeted down the road, but we're being deliberate about our choices so that the launch ramp starts off on solid footing. And as I mentioned before, the team has already been what you'd call rightsized for this opportunity. And from here until launch, the heavy focus is disease state education; and then once the label is clear to us and that launch opportunity is in front of us, we'll be sitting in a great spot.
Greg Harrison
analystThat helps. I'd also like to ask about the Gulf and what's happening with the launch there. Do you have a clearer sense now of what the commercial potential looks like in that region? And what's the right way for investors to view that opportunity?
Cecilia Jones
executiveYes. The operation is something we're watching, and clearly the U.S. remains our number one commercial priority and organization. Then, looking outside the U.S., for us the Gulf represents the second commercial opportunity. Saudi Arabia stands as the largest market within the Gulf. As we've mentioned before, we hold a breakthrough designation in that region, and we're collaborating very closely with the new Bridge team as we move through the regulatory process in Saudi Arabia. Regarding the launch ramp in that region, my thinking ties it more closely to, and sees it as similar to, the dynamics of the European market. It's a national health care system, where approval and price are decided nationally. That said, among the different segments inside Saudi Arabia, in the health care system, for instance, the private sector, the Ministry of Health, and academic institutions, we'll need to engage with those segments in the health care system to make sure formulary access exists, which can take time to build up gradually. Still, the patient numbers point to a large commercial opportunity, and we'll steer through that with NewBridge as appropriate.
Chris Raymond
analystI have two things to ask. First, regarding the repeat studies in PKD — I believe you described ACTIVATE-KIDS and ACTIVATE-KIDS-T as providing understanding for upcoming pediatric efforts in sale and sickle cell. Could you expand a bit on that advantage? Might we see what amounts to a modest pediatric program being assembled there? Or could there be labeling advantages right away stemming from this work? Then for my second question — I realize this has come up many times — about the PDUFA and a possible panel: given how much attention liver injury is getting, companies seldom wish for a panel, yet it seems like with all this scrutiny, it might actually help by shining some light on the matter. Do you have any thoughts on whether you want a panel or not?
Brian Goff
executiveThanks, Chris. Sarah, would you like to begin on both — pediatric.
Sarah Gheuens
executiveSure. I'll begin with pediatrics. We've been saying that this is genuinely useful when pediatric development proves quite difficult, correct? And transfusion trials are likewise quite challenging to conduct; so we've sorted through numerous logistical matters that had to be taken into account for those pediatric trials, and we've now gained experience running these pediatric trials and steering them to successful completion — all of those lessons acquired throughout will carry over to whatever future pediatric trial we conduct. So there's an enormous advantage from genuinely possessing that practical experience, and that will, in fact, affect items such as feasibility, startup, and clinical trial logistics across any of those programs. So we're quite pleased about that. And then, naturally, since we're pursuing a quite comparable route throughout hemolytic anemia in adult development. We progressed from PKD to thalassemia to sickle cell disease, had benefit-risk in the PKD adults, and now in the adults, there are numerous lessons that can be carried over from adults to as well; so broadly speaking, we're simply very enthusiastic about broadening the patient population there; and then naturally, any label negotiation you undertake assists with the subsequent label negotiation too. So numerous advantages throughout. With respect to the PDUFA date and the possibility of a panel, so we're very pleased that the PDUFA date has been announced. So for September 7, we have not been informed that we would be having a panel at this moment; so indeed, panels involve a great deal of work, both for us and for the FDA; so I'm not certain if I still completely concur with the evaluation that we might be hoping for a panel. I would just — I don't know, I think regardless, we will be prepared should it occur; that said, I do think you already have insight into what actually happened because we had the PKD label update with the warning and precaution, which truly underscores what we have observed in the thalassemia patient population; and that evaluation has been agreed upon with the FDA for the label update in PKD; so I think we're fine with this with the current data.
Alec Stranahan
analystWe'd also like to congratulate you on the recent announcements, and we're eager for a jam-packed 2025 that lies ahead. We have just a couple of questions. When you think about the way you're growing your sales team for OPAL, since both of those therapies have now been showcased at large medical conferences, how would you characterize the degree of familiarity among doctors and among patient advocacy organizations? Is that roughly in line with what you'd hoped for? Or do you perhaps still have additional work left in that area? And has that influenced how many representatives you've brought on board for the commercial rollout, or has it not really played a role?
Mark Breidenbach
analystRight, Tsveta, would you like to take that first?
Tsveta Milanova
executiveSure, of course; so to begin with, following a highly rigorous approach, as soon as the results from the energize trial became available, we chose to actually path button and begin adjusting the size of the group that interacts with customers in preparation for launch. Our method for launching, just like with any rare disease product, involves a very thorough process focused on patients, doctors and payers, and making certain we've got the proper structure in place. Specifically, we have already resized the sales team. As we mentioned previously, we had roughly 18 to 20 health cumulative anemia specialists handling PK deficiency for the thalassemia, and because our ITV canals are so well established, that lets us adjust the organization's size in a suitable manner, with the whole thing amounting to approximately twice that number. When it comes to familiarity, our team has been out in the field across the U.S., building connections with the care well community and also with the prescribing physicians, most of whom are community hematologists. And I can share that, just as we anticipated, there is substantial awareness not just of the condition, but also of the possibility of new treatment choices for these individuals and bioline profile, we keep pushing forward with our disease state education efforts aimed at both patients and doctors, and as an organization we maintain strong ties with patient communities and the patient advocacy groups. Sarah and I were actually able to sit down with TIF not long ago, and I can share that the enthusiasm expressed by those groups regarding what PYRUKYND could offer is extremely, extremely strong; so we're putting in hard work to get ready. I can share that we are prepared to launch the team, and at this point it's really about digging deeper and deeper to guarantee that we carry things out very effectively right from the start, given the opportunity in front of us.
Brian Goff
executiveRight. And obviously, prior to receiving the PDUFA date, there was no way for us to know when it would be assigned. So the team has done what any strong prelaunch team does. We've gotten ready for multiple scenarios. Now that we know it's September, Tsveta and the team are making the most of this chance when it comes to disease state awareness from now until that point. And month after month, we've observed ongoing momentum with the KOL community and with community-based treating physicians too. They're performing very well.
Alec Stranahan
analystThen a fast question about pediatric PPD. I'm wondering — to sharpen the point — whether you plan to pursue approval in both transfusion groups, those transfused regularly and those not transfused regularly. And whether you believe approval covering the patient groups might be justified, perhaps because of the totality of data from the 2 studies.
Brian Goff
executiveThat is an < >, yes.
Tsveta Milanova
executiveThat is an < >, indeed. When you posed that question, I did take note of it, yes. So what we see from the 2 trials really backs up the advantages of the total — a favorable benefit-risk profile throughout the patient population. We — in the regularly transfused trial, there are patients, and there remain patients, who need no transfusions at all. That is a hugely meaningful clinical benefit. And then in this trial, we clearly have positive results across the board, statistically significant using both methodologies — the methodology-based one and a frequentist approach. So we're very pleased about that too. And we look forward to, and hope to secure, that broader label for patients with PKD.
Brian Goff
executiveYeah. I realize we're on an investor call, but what really drives us as a company are the stories we hear from patients. These are in PKD, of course, and in general, Pyrukynd is the sole approved treatment for adults. And these children have some who've undergone splenectomy, while others are waiting and might face that as a possibility, and to have this promising data that's clinically relevant in the ACTIVATE-KIDS T trial in transfusion-dependent pediatric patients. And now, with today's data, this is truly compelling, and we will certainly try our hardest to advance that with the regulators at the appropriate moment to make this available for patients.
Lydia Erdman
analystThis is Lydia calling in for Salveen. Nice work on the progress. Perhaps just to build on what was asked before regarding pediatric PKD. Would you mind explaining how moving into the pediatric population might affect the overall opportunity in PKD?
Brian Goff
executiveTsveta.
Tsveta Milanova
executiveYes, definitely. So pediatrics represents roughly 20% of the PKD opportunity. PKD, as we're aware, is an ultrarare disease. When we consider the trial, as Sarah pointed out, it's a strong chance for us to offer a treatment option to patients who need one and currently have none available. But what's really key is that this serves as a starting point for us to keep going with pediatric development across all the remaining indications and take everything we learn there and apply it to thalassemia and possibly cyclical disease down the road.
Brian Goff
executiveYeah, and I just want to back up what Cecilia said before regarding PKD revenue. That accounts for roughly 20% of the population, but it's an ultrarare group. So once more, the way we're viewing PKD for this year — especially given the prep and attention we're putting toward thalassemia — is that we expect revenues to be flat compared with 2024. That said, for pediatrics, it's a meaningful addition once we reach that stage, in terms of treatment optionality for these patients.
Tessa Romero
analystLet's kick things off with a quick financial one from our side. Cecilia, when it comes to your OpEx, how should we frame the way your SG&A expenses will move, and what's the expected pace of that build through 2025 and on into 2026; and regarding R&D, is there anything more you can share with us? Then I've got one more question after that.
Cecilia Jones
executiveAbsolutely. As we've said, we keep managing our cost base proactively, which fits within our disciplined approach to allocating capital. With that said, as Brian laid out earlier, we have 3 buckets, or priorities, in that area. Bucket one is getting ready to make the most of the earlier opportunity, which could bring us back-to-back launches, while also moving the pipeline forward. So when it comes to both SG&A and R&D, growth compared with the prior year is what we expect across the next couple of years. Mining a single line, you'll notice some variability from quarter to quarter, but growth is something we do anticipate on both of those items.
Tessa Romero
analystAll right. And could you put some numbers behind what you mean by growth?
Cecilia Jones
executiveWe haven't provided any specific guidance regarding growth. That said, as I mentioned, we're taking a highly disciplined approach here. As Tsveta noted, we held off until we saw the thalassemia data before beginning the larger ramp in thalassemia; we're following a comparable strategy on < > . Our aim is to be ready, since we don't want to end up in a positive scenario that we weren't prepared for, yet we're going about it in a very disciplined manner.
Tessa Romero
analystAll right. And on top of that, when it comes to the schedule, could you map out for areas outside the United States how you see the timing for approval? Specifically, I have in mind the EU, Saudi Arabia, and the UAE?
Brian Goff
executiveSure. Sarah, would you like to speak to that, and Tsveta can address the commercialization strategy.
Sarah Gheuens
executiveAbsolutely, regarding when the approval comes through — the PDUFA date with the FDA is September 7, and that's already been made public and all of that. For the other agencies, it's not quite the same — they won't proactively hand you a specific day on which they'll grant approval. So it really hinges on how things unfold and how many rounds of questions come up during the review. That said, we're genuinely thrilled about how things are moving forward right now, and we remain on track to deliver.
Tsveta Milanova
executiveRight. And looking at it through the lens of commercialization, like I mentioned before, within the Gulf region — where Saudi Arabia represents the largest opportunity — once approval comes through, you still have to work through access and formulary negotiations with each of the different parts of that country. So the real ramp-up will require a certain amount of time, though not exactly the same as the way European health care systems operate. When it comes to Europe, from a commercialization standpoint, we're also seeking a potential partnership in that region. That way, the moment we secure EMA approval, we'll be in a position to navigate the European health care systems too. As all of you are well aware, in Europe, pricing and reimbursement decisions get made on a country-by-country basis. So once again, there's going to be a delay between the approval and the financial commercialization in Europe as well.
Brian Goff
executiveOkay, thank you very much, Michelle. And many thanks to all of you for joining us on today's call; we're 1.5 months into the beginning of what looks set to be a very busy and exciting year. This is an exciting moment at Agios. We genuinely believe that we're positioned to bring transformative new therapies to patients and to generate significant long-term value for shareholders. So thanks once more, and we hope to talk with you again before long.
Operator
operatorWe appreciate you all joining us. That brings the program to a close, so you're free to leave the call now. Wishing each of you a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Agios Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Agios Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Agios Pharmaceuticals, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.